A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs CNP 520 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms Generation S2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2017 According to an Amgen media release, Amgen and Novartis today announced an expanded collaboration with the Banner Alzheimers Institute (BAI) to initiate a new trial - the Alzheimers Prevention Initiative (API) Generation Study 2.
    • 11 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 02 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top